Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)

Equities research analysts at began coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Stock Performance

Shares of CGIX stock opened at $0.65 on Friday. The business has a 50 day moving average of $0.78 and a two-hundred day moving average of $0.88. Cancer Genetics has a 52 week low of $2.11 and a 52 week high of $17.50.

Cancer Genetics Company Profile

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Recommended Stories

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.